The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Innophos Holdings' revenue will grow 6.7% and EPS will shrink 4.3%.
The average estimate for revenue is $215.2 million. On the bottom line, the average EPS estimate is $0.89.
Last quarter, Innophos Holdings notched revenue of $228.3 million. GAAP reported sales were 16% higher than the prior-year quarter's $197.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.90. GAAP EPS of $1.22 for Q1 were 6.1% higher than the prior-year quarter's $1.15 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 21.4%, 570 basis points worse than the prior-year quarter. Operating margin was 13.6%, 510 basis points worse than the prior-year quarter. Net margin was 12.1%, 100 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $879.5 million. The average EPS estimate is $3.72.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 809 members out of 832 rating the stock outperform, and 23 members rating it underperform. Among 236 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 230 give Innophos Holdings a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Innophos Holdings is outperform, with an average price target of $58.67.
Over the decades, small-cap stocks like Innophos Holdings have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Innophos Holdings to My Watchlist.